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The association between atherosclerotic risk factors and renal
function in the general population.
Background. Generalized atherosclerosis is increasingly rec-
ognized as an important cause of end-stage renal disease
(ESRD). We questioned to what extent atherosclerotic risk fac-
tors determine renal function in the general population.
Methods. We used baseline data of the Prevention of Renal
and Vascular End-Stage Disease (PREVEND) Study. A total
of 8592 subjects, aged 28 to 75 years old, visited the outpatient
clinic for blood pressure and anthropometric measurements,
fasting blood sampling, and delivery of two 24-hour urine col-
lections for creatinine clearance and albuminuria calculations.
Design-based multivariate linear regression was used to esti-
mate renal function.
Results. In a multivariate model, male gender and body mass
index (BMI) were associated with a higher renal function, while
increasing diastolic blood pressure, serum triglycerides, use of
antihypertensive or lipid-lowering medication were associated
with a lower renal function. Age, systolic blood pressure, and
plasma glucose showed an inverse U-shaped relationship with
renal function. Cholesterol/high-density lipoprotein (HDL) ra-
tio, smoking, and antidiabetic medication did not contribute
to explain renal function. The atherosclerotic risk factors were
related to renal function independently of albuminuria or C-
reactive protein (CRP). Albuminuria and CRP itself were also
related to renal function. Following gender and age, BMI, uri-
nary albumin excretion (UAE), and plasma glucose had the
strongest relation with renal function.
Conclusion. We conclude that differences in renal function
in the general population are (partly) explained by various
atherosclerotic risk factors. Some risk factors are associated
with elevated filtration, some with an impaired filtration, and
others with both a higher and a lower renal function.
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The incidence of end-stage renal disease (ESRD) is
increasing, and the number of patients on renal replace-
ment therapy is growing steadily [1, 2]. In the past, ESRD
was mainly due to primary renal diseases such as glomeru-
lonephritis and pyelonephritis or interstitial nephritis,
while presently ESRD is mostly due to type 2 diabetic
nephropathy and generalized atherosclerosis. In fact, di-
abetes, hypertension and renovascular disease are the
main causes of ESRD [2–4].
Besides hypertension and increased glucose other
atherosclerotic risk factors, such as hyperlipidemia, obe-
sity and smoking may also have impact on renal function,
even when no underlying kidney disease is present [3,
5–7]. In addition, markers of generalized atherosclero-
sis, such as an elevated urinary albumin excretion (UAE)
[8–10] and an elevated C-reactive protein (CRP) [11, 12],
have been found to be independently associated with re-
nal function [13–17]. Because the various risk factors can
be influenced by counseling and/or active treatment, it
is of importance to know how and to what extent these
atherosclerotic risk factors are related to renal function in
the general population. A number of epidemiologic stud-
ies related specific risk factors to renal function; however,
only a few looked at an integral approach. These were fur-
thermore performed either in a specific population [18]
or taking into account only a selection of risk factors [3].
We therefore undertook an integral approach at investi-
gating first the association of various atherosclerotic risk
factors, with renal function in the general population. Sec-
ond, we tested whether these associations are mediated
via their relation with albuminuria and CRP.
METHODS
Study design and population
We used the baseline data of the 8592 subjects of the
Prevention of Renal and Vascular End-stage Disease
(PREVEND) Study cohort. The PREVEND Study aims
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to investigate the impact of UAE on renal and cardiovas-
cular disease in the general population. In this study all
inhabitants of the city of Groningen, The Netherlands, in
the range of 28 to 75 years old (N = 85,421), were invited
to answer a short questionnaire and to collect a morn-
ing spot urine. A total of 40,856 spot urine samples were
tested for urinary albumin concentration (UAC). Re-
sponders were less likely to be male than nonresponders
(45.6% versus 54.6%) and had a younger age (49.5 years
versus 51.9 years), but the prevalence of risk factors in our
cohort was in general reasonable comparable to the na-
tional prevalence (hypertension 11.2% versus 8.4%; di-
abetes 2.6% versus 2.1%; smoking 42.2% versus 31.5%;
previous myocardial infarction 3.4% versus 2.5%; and
previous cardiovascular accident 0.8% versus 0.6%). Af-
ter exclusion of pregnancy and subjects using insulin, all
subjects with a UAC of ≥10 mg/L (N = 7768) and a con-
trol group with UAC <10 mg/L (3395) were invited twice
to an outpatient clinic. Subjects filled in an extended ques-
tionnaire giving demographics, cardiovascular and renal
history, smoking status, and the use of oral antidiabetic,
antihypertensive and antilipidemic drugs, and collected
two 24-hour urine samples on 2 consecutive days. We
measured weight, height, and took fasting blood sam-
ples. Blood pressure was automatically measured (Di-
namap XL Model 9300 series device) (Johnson-Johnson
Medical, Inc., Tampa, FL, USA) during 10 minutes on
both visits. Together, 8592 subjects completed both visits.
For the present study we excluded 451 subjects because
of leucocyturia or erythrocyturia, according to dipstick
analysis (leukocytes >75/lL or erythrocytes >50/lL, or
leukocytes = 75 and erythrocytes >5/lL), which makes
the albumin measurement unreliable. Another 72 sub-
jects were excluded because they indicated by question-
naire as having a primary renal disease. This left 8069
subjects for the present analyses. All subjects gave writ-
ten informed consent. The local medical ethics committee
approved the PREVEND Study and the conduct of the
project was in accordance with the guidelines of the dec-
laration of Helsinki.
Measurements and definitions
Body mass index (BMI) was calculated as weight (kg)
divided by square of height (m2). Blood pressure val-
ues given are the mean of the last two recordings of
both days. Smoking was defined as current smoking or
cessation of smoking less than a year before the study.
Triglycerides were measured enzymatically. Creatinine
assessments in blood and urine, serum cholesterol, and
glucose were determined by Kodak Ektachem dry chem-
istry (Eastman Kodak, Rochester, NY, USA), an auto-
matic enzymatic method. A commercially available assay
system was used to assess high-density lipoprotein (HDL)
(Abbott Inc., Abbott Park, IL, USA). The intra- and
interassay variation coefficient of serum creatinine was
0.86% and 1.11%, respectively. For urinary creatinine
the coefficients were 0.90% and 2.90%, respectively. Re-
nal function is measured as creatinine clearance, which is
given as the mean of two 24-hour urinary creatinine ex-
cretions divided by plasma creatinine. Urinary leukocyte
and erythrocyte measurements were done by Nephur-
test + leuco sticks (Boehringer Mannheim, Mannheim,
Germany). UAC was determined by nephelometry with
a threshold of 2.3 mg/L and intra- and interassay coef-
ficients of variation of less than 2.2% and 2.6%, respec-
tively (Dade Behring Diagnostic, Marburg, Germany).
UAE is given as the mean of the two 24-hour urine excre-
tions. High sensitive CRP was also determined by neph-
elometry (threshold 0.175 mg/L and intra- and interassay
coefficient of 4.4% and 5.7%, respectively).
Statistical analyses
The null hypothesis tested was no trend of the vari-
able of interest over the quintiles of creatinine clearance
(General Linear Model). A chi-square test was applied to
investigate if the number of males, smokers, and subjects
using medication had a linear trend over the quintiles of
creatinine clearance.
To be able to study the impact of albuminuria in the
general population, subjects with elevated UAC were
oversampled in the PREVEND Study cohort. We used
design-based linear regression using weighing factors to
correct for the oversampling of subjects with an ele-
vated UAE [19] (STATA, Texas version 8.0). For the
analyses in the present study the response variable of
the multivariate linear regression model was creatinine
clearance. Predictor variables included in the regression
model were gender, age, systolic and diastolic blood pres-
sure, BMI, plasma glucose, serum cholesterol/HDL ratio,
serum triglycerides, smoking, the use of antihyperten-
sive, lipid-lowering, or antidiabetic medication, and CRP
and UAE. Medication use was entered in the regression
model because risk factors as blood pressure, lipids, or
glucose could be altered because of the use of medication.
Visual inspection of the data revealed a curved re-
lationship between creatinine clearance and some of
the explanatory variables. Examination of the curvature
was done by graphic interpretation, and by including
a quadratic term of the variable in the linear regres-
sion model. For optimal residual analysis UAE, plasma
glucose, triglycerides, and CRP were transformed by a
natural logarithm. A two-tailed P value of < 0.05 was con-
sidered significant. The comparison between two models
with more than one degree of freedom was done by an
adjusted Wald test [20]. The analyses were repeated af-
ter validation for urinary collection errors, by exclusion
of subjects with >20% difference in urinary creatinine
excretion between the two 24-hour urine collections, and
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Table 1. Population characteristics according creatinine clearance (mL/min) in quintiles
Creatinine clearance in quintiles P valueTotal for trend
1 2 3 4 5 population quintiles
Creatinine clearance 69.0 (11.3) 88.7 (3.9) 101.8 (3.8) 115.6 (4.4) 142.2 (18.5) 103.5 (26.7)
(mL/min) (<81.7) (81.7–95.3) (95.3–108.3) (108.3–123.8) (>123.8)
Number of subjects 1592 1592 1593 1592 1592 7961
Men% 32.8 36.0 48.6 62.9 78.4 51.7 <0.001a
Age years 55 (13) 50 (13) 48 (12) 46 (12) 45 (10) 49 (13) <0.001a
Systolic blood pressure mm Hg 132 (25) 127 (20) 127 (19) 128 (19) 131 (17) 129 (20) <0.001b
Diastolic blood pressure mm Hg 74 (10) 73 (9) 74 (10) 74 (10) 75 (9) 74 (10) <0.001b
Body mass index kg/m2 25.5 (4.2) 25.3 (3.9) 25.6 (3.9) 26.2 (4.0) 27.8 (4.7) 26.1 (4.2) <0.001a
Cholesterol mmol/L 5.8 (1.2) 5.6 (1.1) 5.6 (1.2) 5.6 (1.1) 5.6 (1.1) 5.6 (1.1) <0.001a
High-density lipoprotein mmol/L 1.4 (0.4) 1.4 (0.4) 1.4 (0.4) 1.3 (0.4) 1.2 (0.3) 1.3 (0.4) <0.001a
Cholesterol/high-density lipoprotein ratio 4.5 (1.7) 4.4 (1.7) 4.5 (1.7) 4.8 (1.8) 5.1 (2.0) 4.7 (1.8) <0.001a
Triglycerides mmol/L 1.2 (0.9–1.7) 1.1 (0.8–1.6) 1.1 (0.8–1.7) 1.2 (0.8–1.7) 1.2 (0.7–1.8) 1.2 (0.8–1.7) <0.001b
Glucose mmol/L 4.8 (1.2) 4.8 (1.2) 4.9 (1.3) 4.9 (1.1) 5.1 (1.2) 4.9 (1.2) <0.001a
Smoking% 37.3 37.6 37.4 38.0 38.4 37.7 0.492
Antihypertensive medication% 19.2 10.6 10.2 9.5 9.0 11.7 <0.001a
Lipid-lowering medication% 9.4 5.7 5.7 5.3 4.0 6.0 <0.001a
Antidiabetic medication% 2.5 1.3 1.7 1.1 1.8 1.7 0.094b
C-reactive protein mg/L 1.5 (0.7–3.4) 1.1 (0.5–2.7) 1.2 (0.5–2.8) 1.1 (0.5–2.6) 1.3 (0.6–3.1) 1.3 (0.6–2.9) <0.001b
Urinary albumin excretion mg/24 hours 7.5 (5.1–17.2) 7.9 (5.7–14.2) 8.8 (6.3–15.6) 9.6 (6.7–16.8) 11.5 (8.1–20.8) 9.2 (6.2–17.1) <0.001a
A total of 673 subjects had missing information on one of the variables included in the regression model.
The mean and standard deviation is given enclosed in parentheses, except for triglycerides, urinary albumin excretion, and C-reactive protein, which are expressed
as median with 25th and 75th percentiles enclosed in parentheses and creatinine clearance as median, SD, and the range enclosed in parentheses.
aP value for linear trend; bP value for quadratic trend.
by using indirect renal function estimates, such as the
Cockcroft-Gault and simplified Modification of Diet in
Renal Disease (MDRD) formula. In addition these anal-
yses were repeated after exclusion of diabetic subjects.
RESULTS
Table 1 shows the characteristics of the population,
when subdivided into quintiles according to creatinine
clearance. In the highest compared to the lowest quin-
tile of creatinine clearance, more subjects were male, had
higher BMI, plasma glucose, and UAE. A U-shaped rela-
tion was shown for systolic blood pressure, diastolic blood
pressure, serum triglycerides, and CRP. In the lowest
quintiles of creatinine clearance subjects had higher age,
serum total cholesterol and HDL cholesterol, but a lower
total cholesterol/HDL ratio. The subjects in the lowest
quintile also used more frequently antihypertensive and
lipid-lowering medication. Over every quintile of creati-
nine clearance a similar number of smokers was present.
No pattern was observed in antidiabetic medication use
over the quintiles of creatinine clearance. Univariately,
the following variables, besides age and gender, were as-
sociated with creatinine clearance: BMI, systolic blood
pressure, glucose, antihypertensive and lipid-lowering
medication, cholesterol/HDL ratio, triglycerides, and di-
astolic blood pressure as was UAE.
The atherosclerotic risk factors BMI, systolic blood
pressure, diastolic blood pressure, glucose, triglycerides
as well as the use of antihypertensive and lipid-lowering
medication, were also in multivariate analyses indepen-
dently associated with creatinine clearance (r2 = 0.31)
(Table 2, model 1). Total cholesterol/HDL ratio, smoking,
and antidiabetic medication were not associated with cre-
atinine clearance. As presented in the multivariate model
(Table 2, model 1), male gender and higher BMI were
associated with a higher creatinine clearance, whereas
higher diastolic blood pressure, serum triglycerides, and
antihypertensive and lipid-lowering medication were as-
sociated with a lower creatinine clearance. Higher age
was also negatively associated with creatinine clearance,
however, in a curvature relation. The use of antihyper-
tensive and lipid-lowering drugs was associated with a
3.5 and 5.1 mL/min lower creatinine clearance. The asso-
ciation between, respectively, systolic blood pressure, and
plasma glucose versus creatinine clearance was an inverse
U-shaped curve. To study if the relation of cardiovascular
risk factors and renal function was mediated by UAE or
CRP, these factors were added to the regression model
(Table 2, model 2). The beta coefficients of the cardiovas-
cular risk factors hardly changed which indicates that the
link between risk factors and renal function is indepen-
dent of UAE and CRP. UAE itself also showed an inverse
U-shaped relation with renal function and the association
between CRP and renal function was negative.
In Figure 1 the association between the atherosclerotic
factors and renal function is visualized. In the multivari-
ate model the ranking order of the variables (starting with
strongest F test) was shown in Table 3, model 1. Table 3,
model 2 shows the ranking order after inclusion of UAE
and CRP in the multivariate model. Starting with the
highest ranking, the ranking order of strength was gen-
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Table 2. Design based multivariate regression model of atherosclerotic risk factors/markers and creatinine clearance as dependent variable
(model 1 is atherosclerotic risk factors and model 2 is atherosclerotic risk factors and markers)
Model 1 Model 2
R2 = 0.31 N = 7689 R2 = 0.39 N = 7396
Beta Standard P value Beta Standard P value
coefficient error P value (Wald statistic)a coefficient error P value (Wald statistic)a
Genderb 17.85 0.76 <0.001 16.14 0.74 <0.001
Age 0.45 0.24 0.56 0.23
Age2 −0.01 2.35 × 10−3 <0.001 −0.01 2.25 × 10−3 <0.001
Body mass index 1.71 0.12 <0.001 1.73 0.11 <0.001
Systolic blood pressure 0.59 0.16 0.54 0.15
Systolic blood pressure2 −1.86 × 10−3 0.54 × 10−3 0.007 −1.89 × 10−3 0.52 × 10−3 0.001
Diastolic blood pressure −0.14 0.06 0.016 −0.18 0.06 0.001
Ln glucose 68.53 11.99 71.34 11.68
Ln glucose2 −13.83 3.31 <0.001 −15.20 3.29 <0.001
Antihypertensive medicationc −3.51 1.25 0.005 −3.27 1.20 0.007
Lipid-lowering medicationc −5.07 1.48 <0.001 −5.07 1.35 <0.001
Ln Triglycerides −4.06 0.76 <0.001 −3.26 0.72 <0.001
Ln urinary albumin excretion 34.53 1.91
Ln urinary albumin exretion2 −4.74 0.30 <0.001
Ln C-reactive protein −0.70 0.33 0.033
Intercept −11.64 15.87 −58.5 15.07
aComposite variables tested by adjusted Wald test.
bReference group of gender is female gender.
cReference group of lipid-lowering or antihypertensive medication is non-users.
der, age, BMI, UAE, plasma glucose, serum triglycerides,
lipid-lowering medication, diastolic blood pressure, an-
tihypertensive medication, systolic blood pressure, and
CRP. BMI lost its high ranking when renal function was
corrected for body surface area (BSA).
The multivariate analysis was repeated after validation
for collection errors; exclusion of subjects with >20% dif-
ference in urinary creatinine excretion between the two
24-hour urine collections. We also repeated the analyses
by using other GFR estimates (Cockcroft-Gault and the
simplified MDRD formulas). These additional analyses
did not change the above-presented results. Analyzing
the linear model explaining BSA corrected creatinine
clearance, lowered the beta coefficient of gender and
BMI (to 5.3 and 0.3, respectively) as compared with non-
BSA correction. However, the other coefficients did not
change substantially. The direction of the associations be-
tween the atherosclerotic factors and renal function did
not change after exclusion of subjects using antihyperten-
sive, lipid-lowering medication, or subjects with diabetes.
DISCUSSION
We found that several atherosclerotic risk factors ex-
plain the variation in renal function in this large cohort
study. The impact of the individual factors (analyzed in
a multivariate setting) varied considerably. Some factors
had a straight linear impact, others interestingly showed
a parabolic or hyperbolic function relation, meaning that
different levels of the explaining parameter had a differ-
ent relation with renal function. Moreover, the patho-
genetic pathway relating atherosclerotic risk factors with
renal function seems to be independent of albuminuria
or low grade inflammation.
Intervention in these factors, such as life style advices
or drug prescription, can ameliorate the risk factors and
may thus be favorable for renal function. As albuminuria
was one of the factors most strongly associated with renal
function, the present data may encourage clinicians to test
for UAE in patients with atherosclerotic risk factors.
These presentations of data are new when compared
to those studies that focused on the relation of renal
function and one atherosclerotic risk factor. We inves-
tigated the integral relation of a number of established
atherosclerotic risk factors to determine the factors with
the largest impact on renal function as a continuous pa-
rameter, whereas other studies classify renal function into
groups which gives no information on the shape of the re-
lation of atherosclerotic risk factors and renal function.
As expected, we found men to have a higher creati-
nine clearance than women, and older subjects to have
a lower creatinine clearance. The age-related decline in
renal function is caused most likely by an involutional
process. It is known from literature that some subjects
show no change in renal function over the years, whereas
in others a manifest decline is observed, suggesting that
the impact of subclinical atherosclerotic pathology may
be more prominent in one subject than the other [21].
We showed a positive association of BMI and creati-
nine clearance, which was still present after correction
of renal function for BSA. These findings are compara-
ble with other reports in literature that show an elevated
GFR in obese subjects [22, 23]. Hyperfiltration is hypoth-
esized to be the underlying mechanism of obesity related
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Fig. 1. Figures of the relation of cardiovascular risk factors and renal function. The equation of the regression model is graphed by using the median
for the covariates, male gender and no medication use.
renal failure [6]. In obese Zucker rats glomerular injury
correlated with hyperphagia-induced glomerular hyper-
filtration which could be prevented by food restriction
[24]. In a previous study we showed that especially an ab-
dominal fat distribution is associated with a diminished
filtration [25].
Haroun et al [26] showed that high-normal blood
pressure is associated with increased risk of develop-
ing chronic kidney disease in a community-based cohort.
Also in a cross-sectional analysis of the NHANES III
population, higher systolic and diastolic blood pressure
and the presence of hypertension were associated with
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Table 3. F test of strength of the association between atherosclerotic risk factors/markers and creatinine clearance (model 1 is atherosclerotic risk
factors and model 2 is atherosclerotic risk factors and markers)
Model 1 Model 2
df (numerator) F test P value Ranking order F test P value Ranking order
Gender 1 548.6 <0.001 1 482.0 <0.001 1
Age 2 345.6 <0.001 2 355.3 <0.001 2
Body mass index 1 217.4 <0.001 3 228.7 <0.001 3
Ln glucose 2 52.8 <0.001 4 51.2 <0.001 5
Ln triglycerides 1 28.8 <0.001 5 20.7 <0.001 6
Lipid-lowering medication 1 11.8 <0.001 6 14.1 <0.001 7
Systolic blood pressure 2 7.3 <0.001 7 6.6 0.001 10
Antihypertensive medication 1 7.9 0.005 8 7.3 0.007 9
Diastolic blood pressure 1 5.8 0.016 9 10.4 0.001 8
Ln urinary albumin excretion 2 188.2 <0.001 4
Ln C-reactive protein 1 4.5 0.033 11
higher serum creatinine levels [27]. In our study systolic
blood pressure had an inverse U-shaped association with
creatinine clearance, and diastolic blood pressure a nega-
tive association. This remarkable observation might indi-
cate that the relation of blood pressure and renal function
is not straight forward. Longitudinal data are required to
explore if blood pressure alters renal function or if the re-
lation is predominantly the inverse. An inverse U-shaped
pattern was also observed for UAE and plasma glucose
in relation to renal function which indicated that it may
be possible that the different levels of UAE or plasma
glucose are not in the same way related to renal function.
Another possibility is that certain unmeasured confound-
ing effects cause these nonlinear relations. Obesity, high
blood pressure, high fasting glucose, and microalbumin-
uria (elevated UAE) are determinants of the metabolic
syndrome and their interaction leads to chronic cardio-
vascular diseases and possibly also to kidney diseases [28,
29]. Combined action of risk factors of the insulin resis-
tance syndrome may be detrimental for renal function.
Triglycerides had a negative association with creatinine
clearance. Cholesterol/HDL ratio was positively associ-
ated to renal function; however, this relation was not in-
dependent of triglycerides. The ARIC study showed in
a population-based sample in the United States that low
HDL cholesterol and hypertriglyceridemia increase the
risk of renal function loss [5, 30]. Dyslipidemia was also in
the Physicians’ Health Study associated with an increased
risk of developing renal dysfunction [5].
As we described previously, CRP was associated with
a diminished filtration [31]. In this study CRP and renal
function were furthermore on the entire level of creati-
nine clearance negatively related. This finding is in con-
trast with longitudinal data of the MDRD Study, which
reported that CRP was not an independent risk factor
for progression of nondiabetic kidney disease in patients
with preexisting renal disease [32]. The difference may be
due to the fact that we analyzed subjects from the general
population, whereas the MDRD Study was performed in
patients with renal disease. Although we previously de-
scribed an association between smoking and both hyper-
filtration and diminished filtration [33], smoking was not
related to creatinine clearance on a continuous scale.
A limitation of the present study is the fact that we mea-
sured renal function as the clearance of creatinine instead
as clearance of specific glomerular filtration rate (GFR)
tracers, such as inulin or iothalamate. Performance of re-
nal function studies with such tracers in a population
study with the size of the current study is, however,
neither feasible nor ethical. Many population studies
use formulas to estimate GFR based on a single serum
creatinine measurement. These formulas have their limi-
tations based on their generalizability to different popu-
lations [34]. The use of creatinine clearance in this study
is therefore an advantage, especially because we used the
mean of two 24-hour creatinine clearances. This mini-
mizes the error caused by incomplete urine collection. We
also examined the robustness of our findings by excluding
subjects with a more than 20% difference in urinary crea-
tinine excretion between the 2 days. A second validation
of renal function estimation was performed by using ei-
ther Cockcroft-Gault and MDRD estimated clearances.
Essentially the same results were observed by using these
validations of renal function. A second limitation of our
study is its cross-sectional character. We cannot conclude
that the parameters associated with either a higher or a
lower creatinine clearance indeed are causally related to
creatinine clearance. Neither can we conclude that treat-
ment of the risk factor will prevent creatinine clearance
to become abnormal. The ongoing follow-up of the PRE-
VEND cohort may give answers to these questions. A
strength of this study is that by using weighing factors
in a design-based linear regression model, the presented
results are generalizable to the general population.
CONCLUSION
In the general population renal function is related to
most of the atherosclerotic risk factors, such as plasma
glucose, BMI, blood pressure, triglycerides, and the use
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of antihypertensive or lipid-lowering medication. In ad-
dition, it is strongly associated with two novel markers of
vascular damage, albuminuria and CRP. The relation of
cardiovascular risk factors and renal function is however,
not mediated by albuminuria or CRP.
Some of the cardiovascular risk factors are associated
with a higher and some with a lower renal function. Inter-
vention in the cardiovascular risk factors and monitoring
albuminuria may contribute to the prevention of renal
function impairment in an early stage.
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